Improving decay-accelerating factor (DAF, CD55) by substituting a GPI-anchor with a membrane-targeting address

被引：0
|
作者：
White, J
Giddings, N
Esser, D
Thurston, K
Steward, M
Bright, JR
Morgan, BP
Smith, GP
Smith, RAG
机构：
[1] AdProTech, Saffron Walden CB10 1XL, Essex, England
[2] Univ Wales Coll Med, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales
来源：
MOLECULAR IMMUNOLOGY | 2001年 / 38卷 / 2-3期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
131
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [21] Towards a CD59-based therapeutic: GPI anchor substitution with a membrane-targeting address
    Rowling, PJE
    White, J
    Mansfield, L
    Steward, M
    Bright, JR
    Lachmann, PJ
    Smith, GP
    Smith, RAG
    MOLECULAR IMMUNOLOGY, 2001, 38 (2-3) : 119 - 120
  • [22] Identification of the 80-kDa LPS-binding protein (LMP80) as decay-accelerating factor (DAF, CD55)
    El-Samalouti, VT
    Schletter, J
    Chyla, I
    Lentschat, A
    Mamat, U
    Brade, L
    Flad, HD
    Ulmer, AJ
    Hamann, L
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1999, 23 (03): : 259 - 269
  • [23] Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CD55)
    Krautkraemer, Ellen
    Zeier, Martin
    JOURNAL OF VIROLOGY, 2008, 82 (09) : 4257 - 4264
  • [24] A MONOCLONAL-ANTIBODY AGAINST HUMAN DECAY-ACCELERATING FACTOR (DAF, CD55), D17, WHICH LACKS REACTIVITY WITH SEMEN-DAF
    HARA, T
    MATSUMOTO, M
    FUKUMORI, Y
    MIYAGAWA, S
    HATANAKA, M
    KINOSHITA, T
    SEYA, T
    AKEDO, H
    IMMUNOLOGY LETTERS, 1993, 37 (2-3) : 145 - 152
  • [25] TEST FOR ABILITY OF DECAY-ACCELERATING FACTOR (DAF, CD55) AND CD59 TO ALLEVIATE COMPLEMENT-MEDIATED DAMAGE OF XENO-ERYTHROCYTES
    MIYAGAWA, S
    SHIRAKURA, R
    MATSUMIYA, G
    NAKATA, S
    MATSUDA, H
    HATANAKA, M
    MATSUMOTO, M
    KITAMURA, H
    SEYA, T
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1993, 38 (01) : 37 - 44
  • [26] Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55)
    Hinchliffe, SJ
    Spiller, OB
    Rushmere, NK
    Morgan, BP
    JOURNAL OF IMMUNOLOGY, 1998, 161 (10): : 5695 - 5703
  • [27] Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo
    Loberg, Robert D.
    Day, LaShon L.
    Dunn, Rodney
    Kalikin, Linda M.
    Pienta, Kenneth J.
    NEOPLASIA, 2006, 8 (01): : 69 - 78
  • [28] Sodium butyrate blocks cytokine-induced decay-accelerating factor (DAF;CD55) expression in human colon cancer cells.
    Andoh, A
    Shimada, M
    Fujiyama, Y
    Bamba, T
    GASTROENTEROLOGY, 2000, 118 (04) : A271 - A271
  • [29] Cytokine-stimulated release of decay-accelerating factor (DAF; CD55) from HT-29 human intestinal epithelial cells
    Nasu, J
    Mizuno, M
    Uesu, T
    Takeuchi, K
    Inaba, T
    Ohya, S
    Kawada, M
    Shimo, K
    Okada, H
    Fujita, T
    Tsuji, T
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1998, 113 (03): : 379 - 385
  • [30] Deficiency of decay accelerating factor (DAF, CD55) enhances T cell responses to antigen immunization
    Liu, J
    Miwa, T
    Hilliard, B
    Chen, YH
    Wells, AD
    Song, WC
    MOLECULAR IMMUNOLOGY, 2004, 41 (2-3) : 269 - 269
12345